Grupos Investigadores

Líneas de Investigación

  • Cáncer de próstata de alto riesgo
  • Cáncer de próstata órgano-confinado: caracterización morfológica y biológica
  • Inmunoterapia en cáncer de próstata
  • Nuevas terapias dirigidas al cáncer de próstata
  • Terapias de rescate trás fracaso de tratamiento inicial

Palabras Clave

  • Cáncer de próstata
  • Cáncer de próstata metastásico
  • Cáncer resistente a la castración
  • Radioterapia
  • Terapia focal

Publicaciones Científicas desde 2018

  • Autores: Aliseda Jover, Daniel; Rotellar Sastre, Fernando; Sancho Rodriguez, Lidia; et al.
    Revista: REVISTA ESPAÑOLA DE MEDICINA NUCLEAR E IMAGEN MOLECULAR
    ISSN: 2253-8089 Vol.42 N° 4 2023 págs. 265 - 271
    Resumen
    Surgical resection is considered the curative treatment par excellence for patients with primary or metastatic liver tumors. However, less than 40% of them are candidates for surgery, either due to non-modifiable factors (comorbidities, age, liver dysfunction¿), or to the invasion or proximity of the tumor to the main vascular requirements, the lack of a future liver remnant (FLR) adequate to maintain postoperative liver function, or criteria of tumor size and number. In these last factors, hepatic radioembolization has been shown to play a role as a presurgical tool, either by hypertrophy of the FLR or by reducing tumor size that manages to reduce tumor staging (term known as "downstaging"). To these is added a third factor, which is its ability to apply the test of time, which makes it possible to identify those patients who present progression of the disease in a short period of time (both locally and at distance), avoiding a unnecessary surgery. This paper aims to review RE as a tool to facilitate liver surgery, both through the experience of our center and the available scientific evidence.
  • Autores: González Padilla, Daniel Antonio (Autor de correspondencia)
    Revista: JOURNAL OF UROLOGY
    ISSN: 0022-5347 Vol.209 N° 4 2023 págs. 682 - 683
  • Autores: Villalabeitia-Ateca, I.; Prieto-Calvo, M.; Martínez de la Cuesta, Antonio; et al.
    Revista: CIRUGÍA ESPAÑOLA
    ISSN: 2173-5077 Vol.101 N° 2 2023 págs. 143 -145
  • Autores: González Padilla, Daniel Antonio (Autor de correspondencia)
    Revista: BJU INTERNATIONAL
    ISSN: 1464-4096 Vol.131 N° 2 2023 págs. 262
    Resumen
    Objectives To set out the second in a series of guidelines on the treatment of urolithiasis by the International Alliance of Urolithiasis that concerns retrograde intrarenal surgery (RIRS), with the aim of providing a clinical framework for urologists performing RIRS.Materials and Methods After a comprehensive search of RIRS-related literature published between 1 January 1964 and 1 October 2021 from the PubMed database, systematic review and assessment were performed to inform a series of recommendations, which were graded using modified GRADE methodology. Additionally, quality of evidence was classified using a modification of the Oxford Centre for Evidence-Based Medicine Levels of Evidence system. Finally, related comments were provided.Results A total of 36 recommendations were developed and graded that covered the following topics: indications and contraindications; preoperative imaging; preoperative ureteric stenting; preoperative medications; peri-operative antibiotics; management of antithrombotic therapy; anaesthesia; patient positioning; equipment; lithotripsy; exit strategy; and complications.Conclusion The series of recommendations regarding RIRS, along with the related commentary and supporting documentation, offered here should help provide safe and effective performance of RIRS.
  • Autores: Miñana López, Bernardino (Autor de correspondencia); Andrés Boville, Guillermo; Barbas Bernardos, Guillermo; et al.
    Revista: JOURNAL OF UROLOGY
    ISSN: 0022-5347 Vol.209 N° 1 2023 págs. 261 - 270
  • Autores: Miñana López, Bernardino (Autor de correspondencia); Andrés Boville, Guillermo; Barbas Bernardos, Guillermo; et al.
    Revista: JOURNAL OF UROLOGY
    ISSN: 0022-5347 Vol.209 N° 1 2023 págs. 270
  • Autores: Gonzalez-Bertolin, I.; Barbas Bernardos, Guillermo (Autor de correspondencia); Suarez, L. G.; et al.
    Revista: EUROPEAN JOURNAL OF PEDIATRICS
    ISSN: 0340-6199 Vol.182 N° 11 2023 págs. 4867-4874
    Resumen
    Urinary tract infections are the initial manifestation in 30% of urinary tract malformations. Identifying these patients, who could benefit from a specific treatment, is still challenging. Hyponatremia during urinary tract infection has been proposed as a urinary tract malformation marker. We evaluate the prevalence of hyponatremia during febrile urinary tract infections and its association with subjacent urinary tract malformations. We performed a retrospective study of healthy patients under 16 years, diagnosed with a first episode of febrile urinary tract infection, who had undergone blood testing in the acute episode and at least one renal ultrasound during follow-up (January 2014-November 2020). Hyponatremia was defined as (serum sodium = 130 mEq/L). According to imaging findings, we classified patients into three groups: normal kidney ultrasound, mild pelviectasis, and significant urinary tract malformation. We performed logistic regression models to identify independent risk factors for urinary tract malformation and mild pelviectasis. We included 492 patients and 2.8% presented hyponatremia. We identified normal ultrasound in 77%, mild pelviectasis in 10.8%, and urinary tract malformation in 12% of patients. We found an association between mild pelviectasis and hyponatremia [OR 6.6 (CI95% 1.6-26.6)]. However, we found no association between hyponatremia and urinary tract malformation. The parameters that were associated with malformations were presenting a non-E. coli infection, C-reactive-protein levels over 80 mg/L, and bacteremia.Conclusion: Hyponatremia during the first episode of febrile urinary tract infection is present in 2.8% of patients and is associated with mild pelviectasis in imaging. However, hyponatremia does not indicate a greater need for complementary tests to screen for urinary tract malformations.
  • Autores: Gonzalez-Bertolin, I.; Barbas Bernardos, Guillermo (Autor de correspondencia); Garcia Suarez, L.; et al.
    Revista: ACTA PAEDIATRICA
    ISSN: 0803-5253 Vol.112 N° 10 2023 págs. 2202 - 2209
    Resumen
    Aim: To describe the prevalence, severity, risk factors, and clinical relevance of electrolyte disturbances and acute kidney injury (AKI) during febrile urinary tract infection (fUTI). Methods: Retrospective observational study of well/fair-appearing patients between 2 months and 16 years, with no previous relevant medical history, diagnosed with fUTI in the paediatric emergency department (PED) with subsequent microbiological confirmation. Analytical alteration (AA) data were considered: AKI (creatinine elevation x 1.5 the median for age), plasma sodium alteration (<= 130 or >= 150 mEq/L), and potassium alteration (<= 3 or >= 6 mEq/L). Results: We included 590 patients, 17.8% presented AA (13 hyponatremia, 7 hyperkalaemia, and 87 AKI). No patient presented severe analytic alterations or a higher frequency of symptoms potentially attributable to these alterations (seizures, irritability, or lethargy). Risk factors associated with these AA were clinical dehydration (OR = 3.5 95% CI: 1.04-11.7; p = 0.044) and presenting a temperature >39 degrees C (OR = 1.9 95% CI: 1.14-3.1; p = 0.013). Conclusions: Electrolyte and renal function disturbances are infrequent in the previously healthy paediatric population with a fUTI. If present, they are asymptomatic and not severe. Based on our results, performing systematic blood analysis to rule out AA appears no longer justified, especially in the absence of risk factors.
  • Autores: Subiela, J. D. (Autor de correspondencia); Faba-Rodríguez, O.; Aumatell, J.; et al.
    Revista: EUROPEAN UROLOGY FOCUS
    ISSN: 2405-4569 Vol.9 N° 2 2023 págs. 325 - 332
    Resumen
    Background: Limited data are available on patients with carcinoma in situ (CIS) of the bladder managed according to current clinical practice guidelines.Objective: To assess the patterns of recurrence, progression to muscle-invasive bladder cancer (MIBC), and upper tract urothelial carcinoma (UTUC) in patients with CIS, and to compare the effectiveness of adequate versus inadequate bacillus Calmette-Guerin (BCG) immunotherapy.Design, setting, and participants: A retrospective analysis of 386 patients with CIS of the bladder with or without associated pTa/pT1 disease treated with BCG between 2008 and 2015.Outcome measurements and statistical analysis: Kaplan-Meier estimations and an inverse probability of treatment weighting (IPTW)-Cox regression were performed to compare recurrence-free survival (RFS) and progression-free survival (PFS) and UTUC incidence over time for patients who received adequate versus inadequate BCG treatment. Results and limitations: The median follow-up was 70.5 mo. At 5 and 10 yr, RFS was 82% and 52%, PFS was 93.6% and 75.8%, and UTUC incidence was 1.7% and 2.9%, respectively. Most recurrence (73.6%) and progression (69.1%) events occurred in the first 3 yr of follow-up, while 38.7% of UTUC incident events were recorded after 5 yr of follow-up. IPTW-Cox regression revealed that patients who received BCG treatment had a lower risk of recurrence (hazard ratio [HR] 0.21, 95% confidence interval [CI] 0.13-0.34), pro-gression (HR 0.46, 95% CI 0.25-0.87), and UTUC incidence (HR 0.24, 95% CI 0.09-0.64). Limitations include the retrospective design and potential selection bias.Conclusions: Patients with CIS of the bladder show a high risk of recurrence, progression, and UTUC incidence. Most of these outcomes occur during the first 3 yr of follow-up, but a significant proportion of the events occur at long-term follow-up. Although receipt of adequate BCG treatment improves outcomes, intensive and long-term surveillance may be warranted.Patient summary: We investigated the long-term cancer control outcomes for patients with carcinoma in situ (CIS; cancerous cells that have not spread from where they first formed) of the bladder. Patients with CIS have a high risk of cancer recurrence and pro-gression. Treatment with bacillus Calmette-Guerin (BCG) improves outcomes.
  • Autores: Salguero, J. (Autor de correspondencia); Chamorro, L.; Gomez-Gomez, E.; et al.
    Revista: EXPERIMENTAL AND CLINICAL TRANSPLANTATION
    ISSN: 1304-0855 Vol.21 N° 6 2023 págs. 481 - 486
    Resumen
    Objectives: Kidney transplant is the optimal treatment for end-stage renal disease; however, due to the imbalance between demand and supply, several strategies have been implemented to increase the donor pool. To increase the number of donors, expanded criteria donors after circulatory death have been explored as an acceptable graft source. In this study, we compared graft survival, estimated glomerular filtration rate at 3 and 5 years, and the incidence of delayed graft function between standard and expanded criteria donors after brain death and between standard and expanded criteria donors after circulatory death. Materials and Methods: A prospective cohort study was conducted between January 1, 2015, and December 31, 2019, at Reina Sofia University Hospital. Variables related to the donor, recipient, and transplant procedure were analyzed, and univariate and multivariate logistic and Cox regression analyses were performed. Results: Our study included 308 deceased donor kidneys. The kidneys from standard criteria brain dead donors had higher estimated glomerular filtration rate than the other groups (P <.03). However, no significant differences in estimated glomerular filtration rate were observed among the suboptimal groups (expanded criteria and standard criteria donors after brain death and expanded criteria donors after circulatory death). The incidence of delayed graft function was significantly higher in expanded criteria donors after circulatory death than in the other groups (odds ratio = 6.9; 95% CI, 2.22-21.71; P <.001). Nevertheless, we found no significant differences in death-censored graft loss among the groups. Conclusions: Kidney transplants from expanded criteria donors and donors after cardiac death are comparable, even when both criteria are combined. The use of expanded criteria donor kidneys after cardiac death is therefore a suitable approach to expand the donor pool, despite the higher risk of delayed graft function, as there were no significant differences in death-censored graft loss.
  • Autores: Calvo Manuel, Felipe; Palma Delgado, Jacobo; Serrano Andreu, Francisco Javier; et al.
    Revista: CLINICAL AND TRANSLATIONAL ONCOLOGY
    ISSN: 1699-048X Vol.25 N° 5 2023 págs. 1268 - 1276
    Resumen
    Introduction: A rapid deploy of unexpected early impact of the COVID pandemic in Spain was described in 2020. Oncology practice was revised to facilitate decision-making regarding multimodal therapy for prevalent cancer types amenable to multidisciplinary treatment in which the radiotherapy component searched more efficient options in the setting of the COVID-19 pandemic, minimizing the risks to patients whilst aiming to guarantee cancer outcomes. Methods: A novel Proton Beam Therapy (PBT), Unit activity was analyzed in the period of March 2020 to March 2021. Institutional urgent, strict and mandatory clinical care standards for early diagnosis and treatment of COVID-19 infection were stablished in the hospital following national health-authorities' recommendations. The temporary trends of patients care and research projects proposals were registered. Results: 3 out of 14 members of the professional staff involved in the PBR intra-hospital process had a positive test for COVID infection. Also, 4 out of 100 patients had positive tests before initiating PBT, and 7 out of 100 developed positive tests along the weekly mandatory special checkup performed during PBT to all patients. An update of clinical performance at the PBT Unit at CUN Madrid in the initial 500 patients treated with PBT in the period from March 2020 to November 2022 registers a distribution of 131 (26%) pediatric patients, 63 (12%) head and neck cancer and central nervous system neoplasms and 123 (24%) re-irradiation indications. In November 2022, the activity reached a plateau in terms of patients under treatment and the impact of COVID pandemic became sporadic and controlled by minor medical actions. At present, the clinical data are consistent with an academic practice prospectively (NCT05151952). Research projects and scientific production was adapted to the pandemic evolution and its influence upon professional time availability. Seven research projects based in public funding were activated in this period and preliminary data on molecular imaging guided proton therapy in brain tumors and post-irradiation patterns of blood biomarkers are reported. Conclusions: Hospital-based PBT in European academic institutions was impacted by COVID-19 pandemic, although clinical and research activities were developed and sustained. In the post-pandemic era, the benefits of online learning will shape the future of proton therapy education.
  • Autores: Castellani, D. (Autor de correspondencia); Traxer, O.; Ragoori, D.; et al.
    Revista: EUROPEAN UROLOGY OPEN SCIENCE
    ISSN: 2666-1691 Vol.52 2023 págs. 51 - 59
    Resumen
    Background: Bilateral kidney stones are commonly treated in staged procedures. Objective: To evaluate outcomes after same-sitting bilateral retrograde intrarenal surgery (SSB-RIRS) for renal stones. Design, setting, and participants: Data from adults who underwent bilateral RIRS in 21 centers were retrospectively reviewed (from January 2015 to June 2022). The inclusion criteria were unilateral/bilateral symptomatic bilateral stone(s) of any size/location in both kidneys and bilateral stones on follow-up with symptom/ stone progression. Stone-free rate (SFR) was defined as absence of any fragment >3 mm at 3 mo. Outcome measurements and statistical analysis: Continuous variables are presented as medians and 25-75th percentiles. A multivariable logistic regression analysis was performed to evaluate independent predictors of sepsis and bilateral SFR. Results and limitations: A total of 1250 patients were included. The median age was 48.0 (36-61) yr. Of the patients, 58.2% were prestented. The median stone diameter was 10 mm on both sides. Multiple stones were present in 45.3% and 47.9% of the left and right kidneys, respectively. Surgery was stopped in 6.8% of cases. The med-ian surgical time was 75.0 (55-90) min. Complications were transient fever (10.7%), fever/infection needing prolonged stay (5.5%), sepsis (2%), and blood transfusion (1.3%). Bilateral and unilateral SFRs were 73.0% and 17.4%, respectively. Female (odds ratio [OR] 2.97, 95% confidence interval [CI] 1.18-7.49, p = 0.02), no antibiotic prophylaxis (OR 5.99, 95% CI 2.28-15.73, p < 0.001), kidney anomalies (OR 5.91, 95% CI 1.96-17.94, p < 0.001), surgical time >100 min (OR 2.86, 95% CI 1.12- 7.31, p = 0.03) were factors associated with sepsis. Female (OR 1.88, 95% CI 1.35- 2.62, p < 0.001), bilateral prestenting (OR 2.16, 95% CI 1.16-7.66, p = 0.04), and the use of high-power holmium:YAG laser (OR 1.63, 95% CI 1.14-2.34, p < 0.01) and thulium fiber laser (OR 2.50, 95% CI 1.32-4.74, p < 0.01) were predictors of bilateral SFR. Limitations were retrospective study and no cost analysis. Conclusions: SSB-RIRS is an effective treatment with an acceptable complication rate in selected patients with kidney stones. Patient summary: In this large multicenter study, we looked at outcomes after same-sitting bilateral retrograde intrarenal surgery (SSB-RIRS) for renal stones in a large cohort. We found that SSB-RIRS was associated with acceptable morbidity and good stone clearance after a single session.& COPY; 2023 The Authors. Published by Elsevier B.V. on behalf of European Association of Urology. This is an open access article under the CC BY-NC-ND license (http://creative-commons.org/licenses/by-nc-nd/4.0/).
  • Autores: Álvarez-Cienfuegos Suárez, Francisco Javier (Autor de correspondencia); Hurtado-Pardo, L.; Breeze, C. E.; et al.
    Revista: CIRUGÍA ESPAÑOLA
    ISSN: 2173-5077 Vol.101 N° 5 2023 págs. 333 - 340
    Resumen
    INTRODUCTION: Laparoscopic resection of the pancreas (LRP) has been implemented to a varying degree because it is technically demanding and requires a long learning curve. In the present study we analyze the risk factors for complications and hospital readmissions in a single center study of 105 consecutive LRPs. METHODS: We conducted a retrospective study using a prospective database. Data were collected on age, gender, BMI, ASA score, type of surgery, histologic type, operative time, hospital stay, postoperative complications, degree of severity and hospital readmission. RESULTS: The cohort included 105 patients, 63 females and 42 males with a median age and BMI of 58 (53-70) and 25.5 (22,2-27.9) respectively. Eighteen (17%) central pancreatectomies, 5 (4.8%) enucleations, 81 (77.6%) distal pancreatectomies and one total pancreatectomy were performed. Fifty-six patients (53.3%) experienced some type of complication, of which 13 (12.3%) were severe (Clavien-Dindo > IIIb) and 11 (10.5%) patients were readmitted in the first 30 days after surgery. In the univariate analysis, age, male gender, ASA score, central pancreatectomy and operative time were significantly associated with the development of complications (P <0.05). In the multivariate analysis, male gender (OR 7.97; 95% CI 1.08-58.88)), severe complications (OR 59.40; 95% CI, 7.69-458.99), and the development of intrabdominal collections (OR 8.97; 95% CI, 1.28-63.02)) were associated with hospital readmission. CONCLUSIONS: Age, male gender, ASA score, operative time and central pancreatectomy are associated with a higher incidence of complications. Male gender, severe complications and intraabdominal collections are associated with more hospital readmissions.
  • Autores: Salguero, J. (Autor de correspondencia); Chamorro, L.; Gómez-Gómez, E. (Autor de correspondencia); et al.
    Revista: JOURNAL OF CLINICAL MEDICINE
    ISSN: 2077-0383 Vol.12 N° 19 2023 págs. 6397
    Resumen
    Background: Delayed graft function (DGF) is a significant challenge in renal transplantation, particularly with deceased donors, necessitating early postoperative dialysis. The prolonged effects of medium- and long-term DGF remain uncertain, marked by contradictory graft survival outcomes. This incongruity might arise from the inherent graft resilience and regenerative capacity during transplantation. This study investigates DGF's impact on graft survival, focusing on grafts displaying favorable (KDRI < 1) and unfavorable outcomes (KDRI ¿ 1). Methods: In this retrospective cohort study (January 2015-December 2019), we assessed kidney transplants at our center, excluding multiorgan simultaneous cases, primary non-functioning grafts, and surgical complications causing graft loss. Patients were categorized into DGF presence or absence groups. Univariate and multivariate analyses, alongside propensity score matching (PSM), were performed. Results: The study encompassed 322 deceased donor kidneys, with 83 encountering DGF. Grafts with higher KDRI indices (KDRI ¿ 1) and DGF exhibited a notably increased graft loss risk (HR: 4.17, 95% CI: 1.93-9.01). However, lower-KDRI donor grafts displayed no significant disparities between the DGF and non-DGF groups. Conclusions: Delayed graft function (DGF) development significantly contributes to graft loss in kidney transplants, particularly in grafts with KDRI ¿ 1.
  • Autores: Garcia Porrero, Guillermo (Autor de correspondencia); Paricio Martínez, José Joaquín; Alvarez Gigli, Laura; et al.
    Revista: REVISTA ESPAÑOLA DE PATOLOGIA
    ISSN: 1699-8855 Vol.56 N° 2 2023 págs. 132 - 135
    Resumen
    Osteoclast-rich undifferentiated carcinoma (ORUC) of the urinary tract is a rare variant of urothelial carcinoma, first described in 1985 by Kitazawa et al. It has a worse prognosis compared to other histological variants of invasive urothelial carcinoma and its diagnosis may prove challenging due to the variability in its immunohistochemical profile. We present a case of ORUC in which GATA3 immunostaining was a useful diagnostic tool.
  • Autores: Subiela, J. D. (Autor de correspondencia); González Padilla, Daniel Antonio; Huguet, J.; et al.
    Revista: UROLOGY
    ISSN: 0090-4295 Vol.172 2023 págs. 157 - 164
    Resumen
    Objective: To assess clinical outcomes of patients who underwent simultaneous radical cystectomy (RC) and radical nephroureterectomy (RNU) for panurothelial carcinoma (PanUC). Materials and methods: A retrospective analysis of 67 patients who underwent simultaneous RC and unilateral RNU for PanUC, from 1996 to 2017. Kaplan-Meier estimates for remnant urothelium recurrence-free survival, metastasis-free survival, overall survival (OS), and cancer-specific survival (CSS) were performed. Cox multivariate models were constructed. Results: The median follow-up was 38 months, 29.8% of patients had a recurrence, 34.3% had metastasis, 67.2% of patients died from any cause, and 37.3% died from urothelial carcinoma. Overall survival and CSS rates at 5 years were 44% and 61%, respectively. In multivariate analysis, progression to muscle-invasive bladder cancer before surgery, presence of muscle-invasive stages at RC and/or RNU, and prostatic urethra involvement were predictors for worse metastasis-free survival and CSS. Forty-one patients (61.2%) had an estimated glomerular filtration rate (eGFR) <60 mL/min before surgery and the number rose to 56 (83.5%) after surgery; 29.8% patients needed renal function replacement therapy after surgery (16 haemodialysis and 4 renal transplant). Conclusion: Patients with PanUC who undergo simultaneous surgery have adverse oncological (only 4 out of every 10 remain alive at 5 years) and functional outcomes (1 out of 3 will need renal function replacement therapy after surgery). Up to a third of the patients had a recurrence (urethra or contralateral kidney) within 18 months, justifying close surveillance or considering prophylactic urethrectomy. These data should help in counsel on morbidity and life expectancy.
  • Autores: Subiela Henriquez, J. D.; Krajewski, W.; Basile, G.; et al.
    Revista: EUROPEAN UROLOGY
    ISSN: 0302-2838 Vol.83 N° Supl. 1 2023 págs. S407 - S408
  • Autores: Romera Caballo, Marta; Bronte Viedma, Angela; Betech Antar, Vicky; et al.
    Revista: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
    ISSN: 1619-7070 Vol.50 N° Supl. 1 2023 págs. S466
  • Autores: Subiela Henriquez, J. D.; Krajewski, W.; Nowak, L.; et al.
    Revista: EUROPEAN UROLOGY
    ISSN: 0302-2838 Vol.83 N° Supl. 1 2023 págs. S394 - S395
  • Autores: Subiela-Henriquez, J. D. ; Krajewski, W.; González Padilla, Daniel Antonio; et al.
    Revista: EUROPEAN UROLOGY
    ISSN: 0302-2838 Vol.83 N° Supl. 1 2023 págs. S399 - S400
  • Autores: Sancho Rodriguez, Lidia; Carballo Menayo, C. ; Gonzalez-Martin, J.; et al.
    Revista: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
    ISSN: 1619-7070 Vol.50 N° Supl. 1 2023 págs. S663
  • Autores: Abad-López, P.; González Padilla, Daniel Antonio; Gómez-Rivas, J.; et al.
    Revista: BRITISH JOURNAL OF SURGERY
    ISSN: 0007-1323 Vol.110 2023
  • Autores: González Padilla, Daniel Antonio (Autor de correspondencia); Subiela, J. D.; González-Díaz, A.; et al.
    Revista: UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
    ISSN: 1078-1439 Vol.40 N° 10 2022 págs. 463
  • Autores: Orcajo-Rincón, J.; Rodríguez Fraile, María Macarena (Autor de correspondencia)
    Revista: REVISTA ESPAÑOLA DE MEDICINA NUCLEAR E IMAGEN MOLECULAR
    ISSN: 2253-654X Vol.41 N° 2 2022 págs. 69 - 70
  • Autores: Aliseda Jover, Daniel; Álvarez-Cienfuegos Suárez, Francisco Javier (Autor de correspondencia); Vivas Pérez, Isabel; et al.
    Revista: REVISTA ESPAÑOLA DE ENFERMEDADES DIGESTIVAS
    ISSN: 1130-0108 Vol.114 N° 3 2022 págs. 168 - 169
    Resumen
    A 56-year-old female was referred to our department with a five-month history of progressive abdominal pain related to physical exertion and copious meals. The pain was located in the mesogastric region and the right flank and remitted when the patient lay in the recumbent position with the knees bent. The patient reported nausea and a weight loss of 12 kg over the previous ten years. She had been diagnosed 18 years previously with hereditary leiomyomatosis and renal cancer and had undergone a hysterectomy and partial nephrectomy.
  • Autores: Rotellar Sastre, Fernando (Autor de correspondencia); Lujan Colas, Juan; Almeida Vargas, Ana; et al.
    Revista: ANNALS OF SURGICAL ONCOLOGY
    ISSN: 1068-9265 Vol.29 N° 9 2022 págs. 5547
  • Autores: García Cortés, Ángel (Autor de correspondencia); Colombas Vives, Juan; Gutiérrez Castañé, Cristina; et al.
    Revista: ACTAS UROLOGICAS ESPAÑOLAS
    ISSN: 0210-4806 Vol.46 N° 5 2022 págs. 275 - 284
    Resumen
    Objetivos Evaluar los resultados de la prostatectomía radical asistida por robot (PRAR), y compararlos con los de la cirugía abierta (PRA) y laparoscópica (PRL). El interés no solo radica en los resultados oncológicos y funcionales de la serie, sino en la evaluación de la calidad de vida (QoL), la recuperación postoperatoria y la satisfacción personal de los pacientes con la intervención (PR), fundamentalmente. Métodos Se realizaron 685 PR en nuestro centro entre 2011-2018 (17,8% PRA, 22,2% PRL y 60% PRAR). Los pacientes fueron evaluados prospectivamente mediante seguimiento hasta abril de 2020, y con la realización un cuestionario múltiple a los 12 meses post-PR, que incluía ICIQ-SF, SHIM, IPSS, IQL y preguntas sobre el dolor, la recuperación postoperatoria y la satisfacción del paciente (SP). También se recogieron datos basales y postoperatorios relacionados con el paciente y el tratamiento, y se realizaron regresiones logísticas binomiales para las comparaciones 1 vs. 1 (PRA vs. PRAR y PRL vs. PRAR). Resultados Los pacientes tratados con PRAR tienen en general menos comorbilidades, menos agresividad tumoral, un requerimiento de mayor tiempo operatorio y un número mayor de márgenes quirúrgicos positivos que los pacientes tratados con PRA y PRL. Sin embargo, la PRAR supera a la PRA en: días de estancia hospitalaria (OR: 0,86; IC 95%: 0,80-0,94), disminución de hemoglobina (OR: 0,38; IC 95%: 0,30-0,47), tasas de transfusión (OR: 0,18; IC 95%: 0,09-0,34), complicaciones tempranas (p = 0,001), IQL (OR: 0,82; IC 95%: 0,69-0,98), función eréctil (OR: 0,41; IC 95%: 0,21-0,79), manejo del dolor (OR: 0,82; IC 95%: 0,75-0,89), recuperación postoperatoria (p < 0,001) y elección de un abordaje diferente (OR: 5,55; IC 95%: 3,14-9,80). La PRAR es superior a la PRL en: continencia urinaria (OR: 0,55; IC 95%: 0,37-0,82), IPSS (OR: 0,96; IC 95%: 0,93-0,98), IQL (OR: 0,76; IC 95%: 0,66-0,88), función eréctil (OR: 0,52; IC 95%: 0,29-0,93), recuperación posquirúrgica (p = 0,02 y 0,004), PS (p = 0,005; 0,002; y 0,03) y elección de un abordaje diferente (OR: 7,79; IC 95%: 4,63-13,13). Conclusiones Los hallazgos de nuestro estudio respaldan la efectividad de la PRAR sobre la PRL y/o la PRA de manera global, tanto en factores funcionales, como en la recuperación postoperatoria, la QoL y la PS. Los resultados oncológicos aún deben ser mejorados.
  • Autores: Rodríguez Fraile, María Macarena (Autor de correspondencia); Tamayo Alonso, P.; Rosales Castillo, Juan Jose; et al.
    Revista: REVISTA ESPAÑOLA DE MEDICINA NUCLEAR E IMAGEN MOLECULAR
    ISSN: 2253-654X Vol.41 N° 2 2022 págs. 126 - 135
    Resumen
    Prostate cancer (PC) is the most common tumor in men in the West and the fifth leading cause of cancer-related death. The use of PSMA radioligands has represented an important advance both in its diagnosis, through PET molecular imaging, and in its treatment in advanced stages of the disease. This article reviews the contribution of PET studies with PSMA radioligands in initial staging, in tumor detection in biochemical recurrence (elevation of PSA) after treatment with curative intent, and in the more advanced stages of the disease (castration resistant PC or CRPC). The contribution of PSMA radioligand therapy (PSMA-RLT) in CRPC patients who progress to standard therapy is also analyzed.
  • Autores: González Padilla, Daniel Antonio (Autor de correspondencia); Subiela, J. D.; Gonzalez-Diaz, A.; et al.
    Revista: UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
    ISSN: 1078-1439 Vol.40 N° 7 2022 págs. 345.e19 - 345.e23
    Resumen
    Introduction: Mitomycin C (MMC) is one of the most frequently utilized intravesical chemotherapy drugs for the management of nonmuscle-invasive bladder cancer (NMIBC). Allergic reactions (Type 4 delayed hypersensitivity) are seldomly reported in the literature but not so infrequent in daily practice, its incidence has been increasing with the use of device-assisted hyperthermia. This study aims to identify the incidence, risk factors, and clinical characteristics of patients with allergic reactions to MMC. Patients and Methods: Single-center retrospective cohort from June 2014 to August 2018. Patients with intermediate or high-risk NMIBC were included. Patients received passive MMC (4 weekly and eleven monthly instillations of 40mg of MMC) or Chemo-hyperthermia (CHT) with MMC (6 weekly and 6-monthly instillations, heated at 43 degrees C [+/- 0.5 degrees C] using Combat BRS). Results: We included 258 patients (MMC = 157, CHT = 101) and found 7 (4.4%) suspected and 4 confirmed (2.4%) allergies in the passive MMC group and 11 suspected (10.9%) and 7 confirmed (6.9%) in the CHT group. The mean number of instillations received before developing the allergy was 6 in the passive MMC and 5 in the CHT group. Seven out of 18 suspected allergy cases were pseudo-allergic reactions with negative allergy tests. Early postoperative MMC instillation was associated with an increased risk of allergy (OR 2.47 [CI 1.39-4.36], P = 0.001), while neither history of atopy nor history of other medications allergy was found to increase the risk. Conclusion: MMC allergy risk is increased with the use of device-assisted hyperthermia with an incidence of 2.4% for passive MMC and 6.9% for CHT. History of prior allergies does not seem to increase the risk of developing MMC allergy. In this series 38% of suspected cases were found to be pseudo-allergic reactions, highlighting the need to confirm the diagnosis before definitively stopping the treatment. (C) 2022 Elsevier Inc. All rights reserved.
  • Autores: Rotellar Sastre, Fernando (Autor de correspondencia); Lujan Colas, Juan; Almeida Vargas, Ana; et al.
    Revista: ANNALS OF SURGICAL ONCOLOGY
    ISSN: 1068-9265 Vol.29 N° 9 2022 págs. 5543 - 5544
    Resumen
    Background: Laparoscopic liver surgery has progressively evolved. Consequently, liver procedures are increasingly performed laparoscopically, particularly in experienced centers. However, vascular resection and reconstruction still are considered a limitation for laparoscopy1 due to the risk of bleeding and the technical difficulty. Methods: A 72-year-old woman with a history of colorectal cancer had a 10 cm metastasis diagnosed in the right hemiliver with tumoral invasion of the right portal branch and tumor thrombus advancing to the portal confluence. After adjuvant chemotherapy and with stable disease, surgical resection was planned.2,3 Tips to avoid portal stenosis were carefully followed. Results: The operation was performed with a fully laparoscopic procedure. To minimize manipulation, an in situ right hepatectomy was performed.4 The right hepatic artery was dissected and ligated. The liver transection was guided with a caudal approach of the middle hepatic vein.5 The right biliary duct was then divided, achieving an excellent exposure of the portal bifurcation. The main and left portal trunks were occluded with vascular clamps, and the right portal vein was sharply divided with scissors. The stump was sutured to minimize backflow bleeding and to cover the tumor thrombus. Then, the portal opening was transversally sutured with a 5/0 running suture. The clamps were released, and the authors observed no bleeding and an adequate caliber with no stenosis. The procedure was completed in the standard fashion. The postoperative course was uneventful, and the woman was discharged on postoperative day 3. No early or late complications were observed.6 CONCLUSIONS: In selected cases, patients who require vascular resection and reconstruction during hepatectomies can benefit from the advantages of a laparoscopic approach.
  • Autores: Lindskog, M.; Laurell, A.; Kjellman, A.; et al.
    Revista: EUROPEAN UROLOGY OPEN SCIENCE
    ISSN: 2666-1691 Vol.40 2022 págs. 38 - 45
  • Autores: Luis Cardo, A. (Autor de correspondencia); Herranz Amo, F.; Rodríguez Cabero, M.; et al.
    Revista: ACTAS UROLOGICAS ESPAÑOLAS
    ISSN: 0210-4806 Vol.46 N° 2 2022 págs. 63 - 69
    Resumen
    Introducción y objetivos Analizar la evolución de la función renal tras nefrectomía parcial (NP) y radical (NR) laparoscópica e identificar factores predictores de deterioro de función renal. Material y método Estudio retrospectivo de pacientes birrenos con filtrado glomerular (FG) > 60 mL/min/1,73 m2 y tumor renal único cT1 tratados en nuestro centro entre los años 2005 y 2018. Resultados 372 pacientes cumplieron los criterios de inclusión para el estudio. 156 (41,9%) fueron tratados mediante NR y 216 (58,1%) mediante NP. Al alta hubo una diferencia de 26,75 mL/min/1,73 m2 de FG entre NR y NP. La edad > 60 años, las complicaciones postoperatorias (OR 2,97, p = 0,005) y NR (OR 10,03, p = 0,0001) fueron factores predictores de FG<60 mL/min/1,73 m2 al alta. Únicamente la NR (OR 7,69, p = 0,0001) se comportó como factor pronóstico independiente de FG<45 mL/min/1,73 m2 al alta. La mediana de seguimiento de la serie fue de 57 (IQR 28 - 100) meses. Al final del seguimiento, nueve (6%) pacientes tratados con NR desarrollaron enfermedad renal crónica (ERC) grave y tres (2%) insuficiencia renal terminal (IRT). Edad > 70 años, diabetes mellitus (DM) (HR 2,12, p = 0,001), hipertensión arterial (HTA) (HR 1,73, p = 0,01) y NR (HR 2,88, p = 0,0001) se comportaron como factores predictores independientes de FG<60 mL/min/1,73 m2. Para un FG<45 mL/min/1,73 m2 fueron edad > 70 años, DM (HR 1,99 IC 95% 1,04 a 3,83, p = 0,04) y NR (HR 5,88 IC 95% 2,57 a 13,45, p = 0,0001). Conclusiones La NR es un factor de riesgo a corto y largo plazo de ERC, aunque con baja probabilidad de ERC grave o IRT en pacientes con FG > 60 mL/min/1,73 m2 preoperatoria. La edad, DM e HTA contribuyen al empeoramiento de la función renal durante el seguimiento.
  • Autores: Guerrero-Ramos, F. (Autor de correspondencia); González-Padilla, D. A.; González-Díaz, A.; et al.
    Revista: WORLD JOURNAL OF UROLOGY
    ISSN: 0724-4983 Vol.40 N° 4 2022 págs. 999 - 1004
    Resumen
    Purpose The purpose of the study was to compare the outcomes of high-risk non-muscle-invasive bladder cancer (HR-NMIBC) patients treated with BCG vs recirculating hyperthermic intravesical chemotherapy (HIVEC) with mitomycin C (MMC). Methods A pilot phase II randomized clinical trial was conducted including HR-NMIBC patients, excluding carcinoma in situ. Patients were randomized 1:1 to receive intravesical BCG for 1 year (once weekly for 6 weeks plus subsequent maintenance) or HIVEC with 40 mg MMC, administered using the Combat BRS system (once weekly instillations were given for 6 weeks, followed by once monthly instillation for 6 months). Total recirculating dwell time for HIVEC was 60 min at a target temperature of 43 degrees +/- 0.5 degrees C. Primary endpoint was recurrence-free survival. Secondary endpoints were time to recurrence, progression-free survival, cancer-specific survival, and overall survival at 24 months. Adverse events were routinely assessed. Results Fifty patients were enrolled. Mean age was 73.5 years. Median follow-up was 33.7 months. Recurrence-free survival at 24 months was 86.5% for HIVEC and 71.8% for BCG (p = 0.184) in the intention-to-treat analysis and 95.0% for HIVEC and 75.1% for BCG (p = 0.064) in the per protocol analysis. Time to recurrence was 21.5 and 16.1 months for HIVEC and BCG, respectively. Progression-free survival for HIVEC vs BCG was 95.7% vs 71.8% (p = 0.043) in the intention-to-treat analysis and 100% vs 75.1% (p = 0.018) in the per protocol analysis, respectively. Cancer-specific survival at 24 months was 100% for both groups and overall survival was 91.5% for HIVEC vs 81.8% for BCG. Conclusion HIVEC provides comparable safety and efficacy to BCG and is a reasonable alternative during BCG shortages.
  • Autores: Geyer, T. (Autor de correspondencia); Kazmierczak, P. M.; Steffen, I. G.; et al.
    Revista: BIOMEDICINES
    ISSN: 2227-9059 Vol.10 N° 5 2022 págs. 1156
    Resumen
    Background: To investigate whole-body contrast-enhanced CT and hepatobiliary contrast liver MRI for the detection of extrahepatic disease (EHD) in hepatocellular carcinoma (HCC) and to quantify the impact of EHD on therapy decision. Methods: In this post-hoc analysis of the prospective phase II open-label, multicenter, randomized controlled SORAMIC trial, two blinded readers independently analyzed the whole-body contrast-enhanced CT and gadoxetic acid-enhanced liver MRI data sets of 538 HCC patients. EHD (defined as tumor manifestation outside the liver) detection rates of the two imaging modalities were compared using multiparametric statistical tests. In addition, the most appropriate treatment recommendation was determined by a truth panel. Results: EHD was detected significantly more frequently in patients with portal vein infiltration (21% vs. 10%, p < 0.001), macrovascular infiltration (22% vs. 9%, p < 0.001), and bilobar liver involvement (18% vs. 9%, p = 0.006). Further on, the maximum lesion diameter in patients with EHD was significantly higher (8.2 cm vs. 5.8 cm, p = 0.002). CT detected EHD in significantly more patients compared to MRI in both reader groups (p < 0.001). Higher detection rates of EHD in CT led to a change in management only in one patient since EHD was predominantly present in patients with locally advanced HCC, in whom palliative treatment is the standard of care. Conclusions: Whole-body contrast-enhanced CT shows significantly higher EHD detection rates compared to hepatobiliary contrast liver MRI. However, the higher detection rate did not yield a significant impact on patient management in advanced HCC.
  • Autores: Seidensticker, M. (Autor de correspondencia); Steffen, I. G.; Bargellini, I.; et al.
    Revista: CURRENT ONCOLOGY
    ISSN: 1198-0052 Vol.29 N° 2 2022 págs. 565 - 577
    Resumen
    The value of gadoxetic acid in the diagnosis of hepatocellular carcinoma (HCC), based on perfusion criteria, is under dispute. This post-hoc analysis of the prospective, phase II, randomized, controlled SORAMIC study compared the accuracy of gadoxetic acid-enhanced dynamic magnetic resonance imaging (MRI) (arterial, portovenous, and venous phase only) versus contrast-enhanced computed tomography (CT) for stratifying patients with HCC to curative ablation or palliative treatment. Two reader groups (radiologists, R1 and R2) performed blind reads of CT and gadoxetic acid-enhanced MRI (contrast dynamics only). A truth panel, with access to clinical and imaging follow-up data, served as reference. Primary endpoint was non-inferiority (margin: 5% points) of MRI vs. CT (lower 95% confidence interval [CI] > 0.75) in a first step and superiority (complete 95% CI > 1) in a second step. The intent-to-treat population comprised 538 patients. Accuracy of treatment decisions was 73.4% and 70.8% for CT (R1 and R2, respectively) and 75.1% and 70.3% for gadoxetic acid-enhanced dynamic MRI. Non-inferiority but not superiority of gadoxetic acid-enhanced dynamic MRI versus CT was demonstrated (odds ratio 1.01; CI 0.97-1.05). Despite a theoretical disadvantage in wash-out depiction, gadoxetic acid-enhanced dynamic MRI is non-inferior to CT in accuracy of treatment decisions for curative ablation versus palliative strategies. This outcome was not subject to the use of additional MR standard sequences.
  • Autores: Luis-Cardo, A. (Autor de correspondencia); Herranz-Amo, F.; Rodríguez-Cabero, M.; et al.
    Revista: ACTAS UROLOGICAS ESPAÑOLAS
    ISSN: 0210-4806 Vol.46 N° 6 2022 págs. 340 - 347
    Resumen
    Introducción y objetivos: Análisis comparativo de complicaciones postoperatorias y supervivencia entre nefrectomía parcial (NP) y radical (NR) laparoscópica en cáncer de células renales (CCR) cT1. Material y método: Estudio retrospectivo de pacientes birrenos con tumor renal único cT1 tratados en nuestro centro entre los a ¿nos 2005 y 2018 mediante NP o NR laparoscópica. Resultados: 372 pacientes cumplieron los criterios de inclusión para el estudio.156 (41,9%) fueron tratados mediante NR y 216 (58,1%) mediante NP. En 10 (4,6%) NP y 6 (3,9%) NR hubo complicaciones Clavien Dindo III-V (p = 0,75). El índice de Charlson se identificó como variable predictora independiente de complicaciones (p = 0,02), no influyendo el tipo de cirugía en el análisis multivariante. La estimación de la supervivencia global (SG) fue de 81,2% y de 56,8% a los 5 y 10 a ¿nos en el grupo de NR y de 90,2% y 75,7% en el grupo de NP respectivamente (p = 0,0001). Se identificaron como factores predictores de mortalidad global la obesidad (HR 2,77, p = 0,01), el índice Charlson ¿3 (HR 3,69,p = 0,001) y el FG <60 mL/min/1,73 m2 al alta (HR 1,87,p = 0,03). El tipo de nefrectomía no demostró influencia en la SG. La estimación de la supervivencia libre de recidiva (SLR) fue de 86,1% a los 5 y 10 a ¿nos en el grupo de NR y de 93,5% y 83,6% en el grupo de NP respectivamente (p = 0,22). Conclusiones: La NP laparoscópica no es inferior a la NR en términos de seguridad oncológica y quirúrgica en el CCR cT1. El tipo de nefrectomía no influyó en la SG del paciente, sin embargo, sí se comportaron como factores predictores la obesidad, el índice Charlson ¿3 y el FG <60 mL/min/1,73 m2 al alta.
  • Autores: Borrego Gómez, J.; Romera, N.; Tellado, J. M.; et al.
    Revista: RADIOLOGIA
    ISSN: 0033-8338 Vol.64 N° 4 2022 págs. 300 - 309
    Resumen
    Background and aims: Magnetic resonance imaging (MRI) with gadoxetic acid is widely used in clinical practice in Spain for the diagnosis, treatment, and follow-up of patients with liver metastases, although its use varies. This paper aims to provide recommendations for the use of MRI with gadoxetic acid in the detection and diagnosis of liver metastases in clinical practice in Spain. Material and methods: This project was undertaken by a group of nine experts who analyzed a series of recommendations about the use of gadoxetic acid extracted from international consensus documents. From this analysis, the experts decided to reject, adopt, contextualize, or adapt each of the recommendations. Once established, the final recommendations were voted on by the same group of experts. Results: The experts reached a consensus about five recommendations related to the use of this imaging technique in the management of liver metastases in three clinical situations: (i) in the detection, (ii) in the diagnosis and preoperative characterization, and (iii) in the detection after a chemotherapy treatment. Conclusion: The results support a clinical benefit for MRI with gadoxetic acid in the detection of liver metastases, favoring preoperative planning, especially in metastases measuring less than 1 cm, thus facilitating early diagnosis of metastatic spread.
  • Autores: Climent Durán, M. A. A.; Pérez Gracia, José Luis; Arranz Arija, J. A.; et al.
    Revista: JOURNAL OF CLINICAL ONCOLOGY
    ISSN: 0732-183X Vol.40 N° 6 2022
  • Autores: Beumer, B.; van Vugt, J.; Sapisochin, G.; et al.
    Revista: JOURNAL OF HEPATOLOGY (ONLINE)
    ISSN: 0168-8278 Vol.77 N° Supl. 1 2022 págs. S815 - S817
  • Autores: Pook, D. W.; Geynisman, D. M.; Carles, J.; et al.
    Revista: JOURNAL OF CLINICAL ONCOLOGY
    ISSN: 0732-183X Vol.40 N° 6 2022
    Resumen
    Purpose: To report the safety and efficacy of ipatasertib (AKT inhibitor) combined with rucaparib (PARP inhibitor) in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with second-generation androgen receptor inhibitors. Patients and Methods: In this two-part phase Ib trial (NCT03840200), patients with advanced prostate, breast, or ovarian cancer received ipatasertib (300 or 400 mg daily) plus rucaparib (400 or 600 mg twice daily) to assess safety and identify a recommended phase II dose (RP2D). A part 1 dose-escalation phase was followed by a part 2 dose-expansion phase in which only patients with mCRPC received the RP2D. The primary efficacy endpoint was prostate-specific antigen (PSA) response (>= 50% reduction) in patients with mCRPC. Patients were not selected on the basis of tumor mutational status. Results: Fifty-one patients were enrolled (part 1 = 21; part 2 = 30). Ipatasertib 400 mg daily plus rucaparib 400 mg twice daily was the selected RP2D, received by 37 patients with mCRPC. Grade 3/4 adverse events occurred in 46% (17/37) of patients, with one grade 4 adverse event (anemia, deemed related to rucaparib) and no deaths. Adverse events leading to treatment modification occurred in 70% (26/37). The PSA response rate was 26% (9/35), and the objective response rate per Response Criteria in Solid Tumors (RECIST) 1.1 was 10% (2/21). Median radiographic progression-free survival per Prostate Cancer Working Group 3 criteria was 5.8 months [95% confidence interval (CI), 4.0-8.1], and median overall survival was 13.3 months (95% CI, 10.9-not evaluable). Conclusions: Ipatasertib plus rucaparib was manageable with dose modification but did not demonstrate synergistic or additive antitumor activity in previously treated patients with mCRPC.
  • Autores: Andrés Boville, Guillermo; Barbas Bernardos, Guillermo; Herranz Amo, F.; et al.
    Revista: EUROPEAN UROLOGY
    ISSN: 0302-2838 Vol.81 N° Suppl. 1 2022 págs. S1219 - S1220
  • Autores: Miñana López, Bernardino; Andrés Boville, Guillermo; Barbas Bernardos, Guillermo; et al.
    Revista: EUROPEAN UROLOGY
    ISSN: 0302-2838 Vol.81 N° Suppl. 1 2022 págs. S500 - S501
  • Autores: Cruz, M.; Rosales Castillo, Juan Jose; Bastidas Tamayo, Juan Fernando; et al.
    Revista: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
    ISSN: 1619-7070 Vol.49 N° Supl. 1 2022 págs. S405 - S406
  • Autores: Morales-Barrera, R.; Castellano, D. E.; O'Donnell, P. H.; et al.
    Revista: JOURNAL OF CLINICAL ONCOLOGY
    ISSN: 0732-183X Vol.40 N° 16 2022
  • Autores: Rosales Castillo, Juan Jose; Bastidas Tamayo, Juan Fernando; Bronte Viedma, Angela; et al.
    Revista: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
    ISSN: 1619-7070 Vol.49 N° Supl. 1 2022 págs. S483
  • Autores: Sotelo, M.; Alonso-Gordoa, T.; Gajate, P.; et al.
    Revista: CLINICAL AND TRANSLATIONAL ONCOLOGY
    ISSN: 1699-048X Vol.23 N° 4 2021 págs. 882 - 891
    Resumen
    Background The studies IMvigor 210 cohort 2 and IMvigor211 evaluated the efficacy of atezolizumab in patients with locally advanced or metastatic urothelial cancer (mUC) upon progression to platinum-based chemotherapy worldwide. Yet, the real impact of this drug in specific geographical regions is unknown. Materials and methods We combined individual-level data from the 131 patients recruited in Spain from IMvigor210 cohort 2 and IMvigor211 in a pooled analysis. Efficacy and safety outcomes were assessed in the overall study population and according to PD-L1 expression on tumour-infiltrating immune cells. Results Full data were available for 127 patients; 74 (58%) received atezolizumab and 53 (42%) chemotherapy. Atezolizumab patients had a numerically superior median overall survival although not reaching statistical significance (9.2 months vs 7.7 months). No statistically significant differences between arms were observed in overall response rates (20.3% vs 37.0%) or progression-free survival (2.1 months vs 5.3 months). Nonetheless, median duration of response was superior for the immunotherapy arm (non-reached vs 6.4 months;p = 0.005). Additionally, among the responders, the 12-month survival rates seemed to favour atezolizumab (66.7% vs 19.9%). When efficacy was analyzed based on PD-L1 expression status, no significant differences were found. Treatment-related adverse events of any grade occurred more frequently in the chemotherapy arm [46/57 (81%) vs 44/74 (59%)]. ...
  • Autores: Hevia Suárez, Mateo (Autor de correspondencia); Robles García, José Enrique; Chiva San Román, Santiago; et al.
    Revista: ACTAS UROLOGICAS ESPAÑOLAS
    ISSN: 0210-4806 Vol.44 N° 2 2020 págs. 103 - 110
    Resumen
    Introduction: Due to the absence of specific instruments to study the psychosocial sphere of patients undergoing extracorporeal shock wave lithotripsy (SWL), the objective of this study is to develop a satisfaction questionnaire regarding the SWL treatment from a health questionnaire which was already designed and had been previously validated. Material and methods: The design of the satisfaction questionnaire was carried out in 5 phases, based on a previously validated health scale in patients treated with SWL (ESPTL), including a total cohort of 135 patients treated at our center who received a phone interview. Phase 1: descriptive analysis of the series and scores of the 8 items of ESPTL. Phase 2: U-Mann Whitney comparison of ESPTL based on the patients' sex. Phase 3: study of ESPTL correlation with age using Spearman's Rho. Phase 4: grouping by factors of ESPTL, comparison by sex and correlation with age, as performed in phases 2 and 3 with the global score. Phase 5: obtaining the satisfaction subscate -SATISLIT-, descriptive analysis, comparison according to sex, correlation with age and linear regression model of SATISLIT with respect to ESPTL. Results: 135 patients, 85(63%) men, 50(37%) women. Median (minimum-maximum) age 56 (27-79) and ESPTL score 31 (8-39). Differences in global ESPTL score between men and women (p <.001), as well as in items 1 (p =.029), 3 (p =.002), 6 (p =.006), 7 (p =.005) and 8 (p =.025). Non-significant correlation of ESPTL regarding age. Significant correlation in items 2, 4, 5 and 8 but, very weak (<0.2). 4 factors, each one with 2 items, with statistically significant differences regarding sex in F2 (p =.001), F3 (p =.007) and F4 (p =.001). Significant correlation with age only in F1 and F3, but very weak (<0.2). Median (minimum-maximum) SATISLIT 18 (4-20). Statistically significant differences regarding patients' sex (p =.001). Non- significant correlation with age (p =.836). Significant linear regression of SATISLIT with respect to ESPTL (p <.001). Conclusions: Based on validated health questionnaire, the present work has provided a new instrument called SATISLIT for assessing patients' satisfaction after treatment with SWL. Future studies with external and temporal validation will be necessary to contrast its real clinical usefulness.
  • Autores: Garcia-Rojo, E.; Medina-Polo, J.; Sopena-Sutil, R.; et al.
    Revista: ACTAS UROLOGICAS ESPANOLAS
    ISSN: 1699-7980 Vol.43 N° 4 2019 págs. 176-181
  • Autores: Ospina-Galeano, I.A.; Medina-Polo, J.; de la Rosa-Kerhmann, S.; et al.
    Revista: UROLOGIA COLOMBIANA
    ISSN: 0120-789X Vol.27 N° 1 2018 págs. 86-91
    Resumen
    Objective¿To assess the efficacy and safety of onabotulinum toxin A in patients with idiopathic overactive bladder inadequately managed with anticholinergics.Materials and Methods¿A prospective, open-label, single centre, and interventional study was conducted, from 2008 to 2013, on consecutive patients with idiophatic overactive bladder that showed lack of efficacy or intolerance to anticholinergic agents.Results¿The study included 73 female patients aged 58.9¿±¿12.9 years. A dose of 100 and 200 units of toxin were administered in 89 and 5 cases, respectively. Nineteen patients received a second injection, 8 patients received 3, and one patient was treated 4 times. Clinically, it was observed that 98% patients had urge urinary incontinence at baseline, as compared with 42% under treatment. Similar results were obtained regarding the number of pads used per day, from 2.8 at baseline to 0.5 after treatment as regards the urodynamic parameters, the first desire to void volume improved from 97¿±¿63 mL to 139¿±¿81 mL. Similar results were obtained as regards cystometric capacity and the volume of the first involuntary detrusor contraction. One patient had a positive urine culture resolved using a conventional oral antibiotic regimen. Intermittent catheterisation was required in 5 patients during the first week.Conclusions¿Onabotulinum toxin A injections significantly improved, not only the clinical symptoms, but also the urodynamic parameters in patients with idiopathic overactive bladder inadequately managed with anticholinergic drugs. This is a simple technique with minimal adverse effects and generally well tolerated.
  • Autores: Unda-Urzai, M.; Cozar-Olmos, J. M.; Miñana López, Bernardino; et al.
    Revista: ACTAS UROLOGICAS ESPANOLAS
    ISSN: 1699-7980 Vol.42 N° 4 2018 págs. 238 - 248
  • Autores: Guerrero-Ramos, Felix; Castellano-Gauna, Daniel; Garcia-Rojo, Esther; et al.
    Revista: ARCHIVOS ESPANOLES DE UROLOGIA
    ISSN: 1576-8260 Vol.71 N° 4 2018 págs. 417 - 425
  • Autores: Pascual Piedrola, Juan Ignacio; Hevia Suárez, Mateo; Ancizu Marckert, Francisco Javier; et al.
    Revista: ARCHIVOS ESPANOLES DE UROLOGIA
    ISSN: 1576-8260 Vol.71 N° 8 2018 págs. 704 - 710
  • Autores: Soria, F.; Villacampa Aubá, Felipe; Serrano, Á.; et al.
    Revista: ARCHIVOS ESPANOLES DE UROLOGIA
    ISSN: 1576-8260 Vol.71 N° 1 2018 págs. 89-96
    Resumen
    Current training in urological endoscopy lacks a specific training program. However, there is a clear need for a specific and uniform program, which will ensure the training, regardless of the unit where it is carried out. So, the goal is to first evaluate the current model and then bring improvements for update. The hospital training accreditation programme are only the adjustment of the official program of the urology specialty to the specific circumstances of each center, which causes variability in training of residents. After reviewing 19 training programs belonging to 12 Spanish regions. The current outlook shows that scarcely 10% of hospitals quantify the number of procedures/year, although the Spanish program emphasizes that the achievement of the residents should be quantified. Urology residents, sense their training as inadequate and therefore their level of satisfaction is moderate. The three main problems detected by residents as an obstacle on their training are: the lack of supervision, tutors completing their own learning. Finally, the lack of quantification in surgical activities is described as a threat. This has no easy solution, since the learning curve of the most common techniques in endourology is not correctly established. Regarding aspects that can improve the current model, they highlight the need to design a specific program. The need to customize the training, the ineludible accreditation of tutors and obviously dignify the tutor¿s teaching activity. Another basic aspect is the inclusion of new technologies as training tools, e-learning. As well as the implementation of an adequate competency assessment plan and the possibility of relying on simulation systems. Finally, they highlight the need to attend monographic meetings and external clinic rotations to promote critical training.

Proyectos desde 2018

  • Título: Desarrollo de inmunoterapia del cáncer basada en mRNA (ARNMUNE)
    Código de expediente: 0011-1411-2023-000101
    Investigador principal: IGNACIO JAVIER MELERO BERMEJO.
    Financiador: GOBIERNO DE NAVARRA
    Convocatoria: 2023 GN PROYECTOS ESTRATEGICOS DE I+D 2023-2026
    Fecha de inicio: 05-09-2023
    Fecha fin: 31-12-2025
    Importe concedido: 422.291,90€
    Otros fondos: Fondos FEDER
  • Título: INtegrative GENomic, digital Imaging and clinical information towars Precision Oncology Optimization ¿ INGENIO
    Código de expediente: PMP21/00107
    Investigador principal: LUIS MONTUENGA BADIA.
    Financiador: INSTITUTO DE SALUD CARLOS III
    Convocatoria: FIMA 2021 Proyectos de I+D+I vinculados a la Medicina Personalizada y Terapias Avanzadas
    Fecha de inicio: 21-03-2023
    Fecha fin: 31-12-2024
    Importe concedido: 153.673,04€
    Otros fondos: Fondos MRR
  • Título: RICORS2040
    Código de expediente: RD21/0005/0024
    Investigador principal: NURIA GARCIA FERNANDEZ.
    Financiador: INSTITUTO DE SALUD CARLOS III
    Convocatoria: 2021 AES Redes de Investigación cooperativa orientadas a resultados (RICORS)
    Fecha de inicio: 01-01-2022
    Fecha fin: 31-12-2024
    Importe concedido: 105.765,00€
    Otros fondos: Fondos FEDER
  • Título: Nuevas estrategias de radio-inmunoterapia para el tratamiento del fracaso loco-regional en cáncer de mama triple negativo
    Código de expediente: 34/2021
    Investigador principal: RAFAEL MARTINEZ MONGE.
    Financiador: GOBIERNO DE NAVARRA. DEPARTAMENTO DE SALUD
    Convocatoria: 2021 GN Proyectos de Investigación en salud
    Fecha de inicio: 23-12-2021
    Fecha fin: 22-12-2024
    Importe concedido: 79.982,51€
    Otros fondos: -
  • Título: Desarrolo preclinico y translacional de una estrategia inmunoterapia intratumoral consitente en la combinacion de BO-112 y agonistas de STING
    Código de expediente: PDC2021-121769-C22
    Investigador principal: JOSE LUIS PEREZ GRACIA.
    Financiador: AGENCIA ESTATAL DE INVESTIGACION
    Convocatoria: 2021 AEI Proyectos de I+D+i para la realización de pruebas de concepto
    Fecha de inicio: 01-12-2021
    Fecha fin: 30-06-2024
    Importe concedido: 23.000,00€
    Otros fondos: -
  • Título: Aplicaciones del estudio multi-ómico de la microbiota al desarrollo de soluciones biotecnológicas innovadoras en el área de la salud (microBiomics)
    Código de expediente: 0011-1411-2021-000106
    Investigador principal: MARIA TERESA HERRAIZ BAYOD, MARIA TERESA HERRAIZ BAYOD, MARIA TERESA HERRAIZ BAYOD.
    Financiador: GOBIERNO DE NAVARRA
    Convocatoria: 2021 GN PROYECTOS ESTRATEGICOS DE I+D 2021-2024
    Fecha de inicio: 15-04-2021
    Fecha fin: 29-02-2024
    Importe concedido: 366.577,17€
    Otros fondos: -
  • Título: Registro prospectivo de hipofraccionamiento con fotonterapia y protonterapia con sobreimpresion en zona GaPSMA positiva en el rescate tras prostatectomia
    Código de expediente: pi20/01598
    Investigador principal: FELIX MAURICIO CAMBEIRO VAZQUEZ.
    Financiador: INSTITUTO DE SALUD CARLOS III
    Convocatoria: 2020 AES Proyectos de investigación
    Fecha de inicio: 01-01-2021
    Fecha fin: 31-12-2024
    Importe concedido: 68.970,00€
    Otros fondos: Fondos FEDER
  • Título: Identificación de biomarcadores para la detección de radionecrosis en pacientes tratados con radioterapia estereopática y desarrollo experimental de nuevas terapias para su prevención.
    Código de expediente: PI20/01531
    Investigador principal: JOSE JAVIER ARISTU MENDIOROZ.
    Financiador: INSTITUTO DE SALUD CARLOS III
    Convocatoria: 2020 AES Proyectos de investigación
    Fecha de inicio: 01-01-2021
    Fecha fin: 31-12-2024
    Importe concedido: 123.420,00€
    Otros fondos: Fondos FEDER
  • Título: Administración intratumoral de agentes inmunoterápicos y radioterapia para potenciar los efectos sistémicos y locales antitumorales
    Código de expediente: PI20/00434
    Investigador principal: MARIA ESPERANZA RODRIGUEZ RUIZ.
    Financiador: INSTITUTO DE SALUD CARLOS III
    Convocatoria: 2020 AES Proyectos de investigación
    Fecha de inicio: 01-01-2021
    Fecha fin: 31-12-2023
    Importe concedido: 111.320,00€
    Otros fondos: Fondos FEDER
  • Título: Liderazgo e INnovación en inmunoTERapia del cáncer desde NAvarra
    Código de expediente: 0011-1411-2020-000078
    Investigador principal: IGNACIO JAVIER MELERO BERMEJO.
    Financiador: GOBIERNO DE NAVARRA
    Convocatoria: 2020 GN PROYECTOS ESTRATEGICOS DE I+D 2020-2022
    Fecha de inicio: 01-09-2020
    Fecha fin: 30-11-2022
    Importe concedido: 596.040,00€
    Otros fondos: -
  • Título: platafoRma de intElIgeNcia artiFicial para la predicción de tOxicidad y Recurrencia del CancE
    Código de expediente: 0011-1411-2020-000074
    Investigador principal: JAVIER RODRIGUEZ RODRIGUEZ, JAVIER RODRIGUEZ RODRIGUEZ.
    Financiador: GOBIERNO DE NAVARRA
    Convocatoria: 2020 GN PROYECTOS ESTRATEGICOS DE I+D 2020-2022
    Fecha de inicio: 22-06-2020
    Fecha fin: 30-11-2022
    Importe concedido: 212.396,26€
    Otros fondos: -
  • Título: Evaluación de YES1 como nueva diana terapéutica y biomarcador de respuesta a dasanitib en cáncer de pulmón.
    Código de expediente: PI19/00230
    Investigador principal: ALFONSO CALVO GONZALEZ.
    Financiador: INSTITUTO DE SALUD CARLOS III
    Convocatoria: 2019 AES Proyectos de investigación
    Fecha de inicio: 01-01-2020
    Fecha fin: 31-12-2022
    Importe concedido: 127.050,00€
    Otros fondos: Fondos FEDER
  • Título: Modelando inmnunoterapia del cáncer de riñón en ratones humanizados
    Código de expediente: PI19/00668
    Investigador principal: MIGUEL FERNANDEZ DE SANMAMED GUTIERREZ.
    Financiador: INSTITUTO DE SALUD CARLOS III
    Convocatoria: 2019 AES Proyectos de investigación
    Fecha de inicio: 01-01-2020
    Fecha fin: 31-12-2023
    Importe concedido: 111.320,00€
    Otros fondos: Fondos FEDER
  • Título: Neurodegeneración en epilepsia: ¿Una nueva Taupatía no descrita? Estudio in-vivo del depósito de proteina Tau en epilepsia temporal
    Código de expediente: PI19/00610
    Investigador principal: MARIA CENTENO SOLADANA, ASIER GOMEZ IBAÑEZ, ASIER GOMEZ IBAÑEZ.
    Financiador: INSTITUTO DE SALUD CARLOS III
    Convocatoria: 2019 AES Proyectos de investigación
    Fecha de inicio: 01-01-2020
    Fecha fin: 30-06-2024
    Importe concedido: 75.020,00€
    Otros fondos: Fondos FEDER
  • Título: Disección de los mecanismos de las recidivas locales post-resección y post braquiterapia.
    Código de expediente: PI19/01884
    Investigador principal: RAFAEL MARTINEZ MONGE.
    Financiador: INSTITUTO DE SALUD CARLOS III
    Convocatoria: 2019 AES Proyectos de investigación
    Fecha de inicio: 01-01-2020
    Fecha fin: 31-12-2022
    Importe concedido: 93.170,00€
    Otros fondos: Fondos FEDER
  • Título: Ensayo clínico fase I/II: nuevo enfoque terapéutico para el tratamiento de tumores sólidos con metástasis hepática.
    Código de expediente: RTC2019-006860-1
    Investigador principal: MARIA ESPERANZA RODRIGUEZ RUIZ.
    Financiador: MINISTERIO DE CIENCIA, INNOVACIÓN Y UNIVERSIDADES
    Convocatoria: 2019 AEI RETOS COLABORACIÓN
    Fecha de inicio: 01-01-2020
    Fecha fin: 30-06-2024
    Importe concedido: 594.994,75€
    Otros fondos: -
  • Título: EHGNA: Desarrollo de Algoritmos de respuesta al tratamiento nutricional frente a la EHGna: integración de datos mediante inteligencia artificial
    Código de expediente: 0011-1383-2020-000010 PC082 EHGNA
    Investigador principal: ITZIAR ABETE GOÑI.
    Financiador: GOBIERNO DE NAVARRA
    Convocatoria: 2020 GN Proyectos Colaborativos
    Fecha de inicio: 01-12-2019
    Fecha fin: 30-11-2022
    Importe concedido: 193.350,00€
    Otros fondos: -
  • Título: Optimización de la radiembolización hepática mediante un modelo de simulación computacional
    Código de expediente: PI18/00692
    Investigador principal: JOSE IGNACIO BILBAO JAUREGUIZAR, MARIA MACARENA RODRIGUEZ FRAILE.
    Financiador: INSTITUTO DE SALUD CARLOS III
    Convocatoria: AES2018 PI
    Fecha de inicio: 01-01-2019
    Fecha fin: 31-12-2022
    Importe concedido: 59.290,00€
    Otros fondos: Fondos FEDER
  • Título: Profundización en la vía del Enpp1: efectos autónomos e implicaciones para la radioterapia del cáncer de mama triple negativo
    Investigador principal: RAFAEL MARTINEZ MONGE
    Financiador: ASOCIACION ESPAÑOLA CONTRA EL CANCER
    Convocatoria: 2023 AECC Clínico Senior
    Fecha de inicio: 15-09-2023
    Fecha fin: 14-09-2027
    Importe concedido: 240.000,00€
  • Título: IL-8/CXCR pathway modulation plus CD137 co-stimulation as a way to overcome resistance to PD-1/PD-L1 pathway blockade in melanoma and kidney cancer patients
    Investigador principal: MIGUEL FERNANDEZ DE SANMAMED GUTIERREZ
    Financiador: ASOCIACION ESPAÑOLA CONTRA EL CANCER
    Convocatoria: 2021 AECC Lab AYUDAS A PROYECTOS DE INVESTIGACIÓN (Grupos emergentes)
    Fecha de inicio: 01-12-2021
    Fecha fin: 30-11-2024
    Importe concedido: 300.000,00€
  • Título: Rediseño del impacto de la radioterapia en el cáncer de mama con nuevos actores: Papel de las células tumorales circulantes (CTC) y nuevas vulnerabilidades de base mecanística.
    Investigador principal: RAFAEL MARTINEZ MONGE
    Financiador: ASOCIACION ESPAÑOLA CONTRA EL CANCER
    Convocatoria: 2021 AECC Proyectos Estratégicos
    Fecha de inicio: 01-10-2021
    Fecha fin: 30-09-2024
    Importe concedido: 150.000,00€
  • Título: Organ - specific biomarkers and therapies to improve the managemente of brain mestastasis
    Investigador principal: ALFONSO CALVO GONZALEZ, ALFONSO CALVO GONZALEZ
    Financiador: FUNDACIO "LA MARATO DE TV3"
    Convocatoria: 2019 FD LA MARATÓ PROYECTOS DE INVESTIGACIÓN
    Fecha de inicio: 22-09-2020
    Fecha fin: 31-01-2024
    Importe concedido: 125.000,00€
  • Título: Potenciación de la citotoxicidad dependiente de anticuerpo mediada por linfocitos nk para inmunoterapia del cáncer
    Investigador principal: IGNACIO JAVIER MELERO BERMEJO
    Financiador: ASOCIACION ESPAÑOLA CONTRA EL CANCER
    Convocatoria: 2015 AECC G Traslacionales
    Fecha de inicio: 01-07-2015
    Fecha fin: 30-06-2022
    Importe concedido: 334.000,00€